UK Community Advisory Board (UK-CAB)

UK-CAB 33 – African treatment issues and late diagnosis

Friday 19 March 2010

At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1

09:30 – 10:00 Registration, refreshments and expenses
10:00 – 10:05 Welcome and UKCAB updates
10:05 – 11:00 African Treatment Issues and Late Diagnosis Dr Ade Fakoya, HIV Consultant

  • Clinical Issues
  • HPA Late Diagnosis data
11:00 – 11:15 Break
11:15 – 12:15 Issues for African sub-groups:

  • Men – Jabulani Chwaula, AHPN, NAHIP
  • MSM – Bisi Alimi, NAZ project
  • Women – Beatrice Osoro, Positively Women
  • Young People
12:15 – 12:30 Pre-Meeting for Gilead – Brian West
12:30 – 14:00 Lunch
14:00 – 15:00 Company meeting: Gilead
15.00 – 15.15 Break
15:15 – 15:45 CROI Feedback
15:45 – 16:00 UKCAB AOB
16.00 Close

Background Reading

This year BHIVA videoed the London feedback meeting and webcasts are now online with slides. This is an alternative way to prepare for Fridays CAB meeting.

Please go to the BHIVA website for the following downloads:

Videos of the speakers presentations from the London meeting held on Monday 1 March 2010 were recorded and can be viewed at:

Please use the link below to download the slides
(For BHIVA members only – login required)

Race Troubles: Why Do African-Americans With HIV Fare Worse?

Efavirenz-related studies: genetics, smoking and TDM 2009

HIV report in the UK:

Gilead’s HIV Pill Works in Mid-Stage Study

42% of Africans with HIV in UK are diagnosed late

HIV prevention for UK Africans should prioritise work with men

UK Africans ‘need more HIV help’

New criteria proposed for late HIV diagnosis

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.